Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study

NCT06599463 is registered in ClinicalTrials.gov with ARCAGY/ GINECO GROUP as lead sponsor.

NCT NCT06599463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06599463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study
Lead sponsor
ARCAGY/ GINECO GROUP
Phase
Observational
Overall status
Completed
Start date
August 19, 2024
Completion date
February 28, 2025
Enrollment
351 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic endometrial cancer